Ocuphire Pharma Results

APX3330 has the Potential to be First Line of Therapy for DR Patients Efficacy Signal Percent of patients on APX3330 with a ≥ 2 step improvement on the DRSS score at week 24 (and 52) compared to placebo in 2 well-controlled, multi-center clinical trials Safety Approval depends on a product's benefit outweighing its risks in the intended population - this benefit should be evaluated in multi-center, 2-year clinical trials Non-Invasive Treatment Option FDA does not require comparative arm of approved anti-VEGF injections such as Eylea for DR Ocuphire Eylea® label; APX3330 Investigator Brochure, ZETA-1 clinical trial PHARMA FDA Guidance Physician/ Patients Efficacy Signal Clinically meaningful decrease in diabetic retinopathy severity with APX3330 ● ● Safety ● Early intervention with oral may reduce progression to vision threatening DR into DME ● Non-Invasive Treatment Option Eylea, although approved, is currently not used as standard of care because of the treatment burden for asymptomatic DR patients Ability to be prescribed by all eye care doctors. Oral option increases global access, especially in underserved regions ● No major organ toxicities Well-tolerated (e.g., AEs acceptable if mild and infrequent for oral) 52

View entire presentation